SCHEMBL15030560

SCHEMBL15030560

COc1ccc(OC(F)(F)F)cc1C(=O)Cn1cccc(C)c1=O

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.43
▸ KDM4E B2RXH2 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ HCRTR1 O43613 4/20 0.39
▸ HCRTR2 O43614 4/20 0.39
▸ SCN8A Q9UQD0 1/20 0.39
▸ SCN10A Q9Y5Y9 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ MAPT P10636 3/20 0.39
▸ TSHR P16473 1/20 0.39
▸ CHRM5 P08912 1/20 0.39
▸ LCLAT1 Q6UWP7 1/20 0.39
▸ P2RX7 Q99572 2/20 0.38
▸ TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15030419 0.89 KMT2A (0.58) KMT2ANPSR1KDM4EALDH1A1CYP3A4
SCHEMBL16806639 0.84 KMT2A (0.47) KMT2ANPSR1KDM4EALDH1A1SMN1; SMN2
SCHEMBL15030565 0.82 ALDH1A1 (0.51) KMT2AKDM4EALDH1A1CYP3A4CYP2C19
SCHEMBL15030513 0.80 RAB9A (0.58) KMT2AALDH1A1SMN1; SMN2MEN1MAPT
SCHEMBL16806638 0.78 IDO1 (0.45) KMT2AKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL15030561 0.77 SMN1; SMN2 (0.45) KMT2AKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL15030562 0.75 PDE4B (0.61) KDM4EALDH1A1
SCHEMBL15030487 0.74 ALDH1A1 (0.52) KMT2AKDM4EALDH1A1CYP3A4CYP2C19
SCHEMBL16809415 0.74 MEN1 (0.49) KMT2ANPSR1KDM4EALDH1A1SCN8A
SCHEMBL15030415 0.73 ALDH1A1 (0.56) KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160340349-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-11-24 — — US disclosed
US-9447072-B2 Pyridone derivative and pharmaceutical containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-09-20 — — US disclosed
US-20160168540-A1 COMPOSITION FOR MAINTAINING PLATELET FUNCTION KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-06-16 — — US disclosed
EP-3006029-A1 COMPOSITION FOR MAINTAINING PLATELET FUNCTION Kaken Pharmaceutical Co., Ltd. (JP) 2016-04-13 — — EP disclosed
US-20150166506-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2015-06-18 — — US disclosed
WO-2013085016-A1 PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME 科研製薬株式会社 (JP) 2013-06-13 — — WO disclosed
WO-2013085017-A1 PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME 科研製薬株式会社 (JP) 2013-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160340349-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME PLPBP, PDXK, PNPO KMT2A 2609/4885NPSR1 1420/4885KDM4E 1409/4885
US-20160168540-A1 COMPOSITION FOR MAINTAINING PLATELET FUNCTION PF4, F2, PFKP KMT2A 4643/4885NPSR1 2471/4885KDM4E 4157/4885
US-20150166506-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME PLPBP, PDXK, PNPO KMT2A 2609/4885NPSR1 1420/4885KDM4E 1409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback